Evotec and UCB sign multi-year CNS pharmacology agreement
Evotec AG announced a collaboration with UCB to provide a broad range of in vitro pharmacology services.
Under the terms of the three-year agreement, Evotec will support UCB's in vitro pharmacology team in drug discovery projects across multiple target classes, particularly in the CNS space. Key activities will include assay development, compound profiling and mechanistic studies and will provide UCB with access to key Evotec expertise in the field of in vitro pharmacology and electrophysiology.
Dr Mario Polywka, Chief Operating Officer of Evotec, commented: "Through this significant collaboration focusing on CNS pharmacology, we continue to strengthen our relationship with UCB, a strategic partner of Evotec. With both teams already working closely together, we look forward to adding value to UCB's drug discovery programmes."
Dr Neil Weir, Senior Vice President of Discovery at UCB, added: "Evotec has demonstrated its scientific excellence and as such is a key partner supporting our drug discovery efforts. We welcome the addition of CNS pharmacology, where Evotec has specific expertise, to the range of activities we collaborate on."
No financial details were disclosed.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Pregnancy remodels the brain - Stem cells shape the sense of smell in mothers
How to quell a cytokine storm: New ways to dampen an overactive immune system - Penn Medicine, University of Leeds findings have implications for new drug targets for lupus, other autoimmune disorders
Sanofi invests in new vaccine production facility in France
Monoamine oxidase A: biomarker for postpartum depression - Postpartum mood swings correlated with high monoamine oxidase A binding
Study links vitamin D to lung cancer survival - U-M researchers find high levels of enzyme that blocks vitamin D can predict lung cancer survival, U-M study finds
Isospec Analytics SA - Lausanne, Switzerland
Innovative therapy method for the treatment of brain tumors
Allon Therapeutics announces davunetide receives FDA Fast Track Status for treatment of Progressive Supranuclear Palsy
